GN Tobacco Use Survey
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00121368|
Recruitment Status : Completed
First Posted : July 21, 2005
Last Update Posted : November 25, 2013
|Condition or disease|
Smoking is regarded as one of the few potentially preventable factors associated with low birth weight, very preterm birth and perinatal death. In an effort to determine the prevalence of tobacco use (smoking and smokeless tobacco) and to collect relevant data in support of a potential smoking prevention or cessation intervention, a multi-site tobacco use survey is being conducted in several countries. The survey will be used to obtain information on knowledge, attitudes and behaviors among pregnant women in diverse populations regarding tobacco products.
The primary outcome is tobacco use status during pregnancy. Secondary outcomes include: knowledge and attitudes regarding tobacco products, health hazards of tobacco use and environmental tobacco smoke (ETS) exposure.
Sample size of 750 per country was calculated under the assumptions that the prevalence of tobacco use could be as low as 0.05 with a coefficient of variation of approximately 15% and a prevalence of 0.10 with a CV of approximately 11%.
|Study Type :||Observational|
|Actual Enrollment :||6000 participants|
|Official Title:||Survey on Tobacco Use in the GN Sites|
|Study Start Date :||February 2004|
|Primary Completion Date :||May 2005|
|Study Completion Date :||May 2005|
- Tobacco use [ Time Frame: Cross sectional ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00121368
|Buenos Aires, Argentina|
|Guatemala City, Guatemala|
|Bhubaneswar, Orissa, India|
|Principal Investigator:||Michele Bloch, MD, PhD||National Cancer Institute (NCI)|